KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Shares Outstanding
Others
Ratios

AbCellera Biologics (ABCL) Operating Income (2020 - 2023)

Historic Operating Income for AbCellera Biologics (ABCL) over the last 4 years, with Q4 2023 value amounting to -$66.1 million.

  • AbCellera Biologics' Operating Income fell 7484.51% to -$66.1 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$237.2 million, marking a year-over-year decrease of 20955.84%. This contributed to the annual value of -$314.8 million for FY2024, which is 3269.68% down from last year.
  • According to the latest figures from Q4 2023, AbCellera Biologics' Operating Income is -$66.1 million, which was down 7484.51% from -$54.9 million recorded in Q3 2023.
  • AbCellera Biologics' Operating Income's 5-year high stood at $225.0 million during Q1 2022, with a 5-year trough of -$66.1 million in Q4 2023.
  • For the 4-year period, AbCellera Biologics' Operating Income averaged around $21.2 million, with its median value being -$4.6 million (2020).
  • Data for AbCellera Biologics' Operating Income shows a peak YoY increase of 754929.31% (in 2021) and a maximum YoY decrease of 148914.03% (in 2021) over the last 5 years.
  • Over the past 4 years, AbCellera Biologics' Operating Income (Quarter) stood at $160.8 million in 2020, then tumbled by 49.28% to $81.6 million in 2021, then plummeted by 146.32% to -$37.8 million in 2022, then crashed by 74.85% to -$66.1 million in 2023.
  • Its Operating Income stands at -$66.1 million for Q4 2023, versus -$54.9 million for Q3 2023 and -$51.4 million for Q2 2023.